{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:15:18Z","timestamp":1790054118204,"version":"4.0.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Pancreatic adenocarcinoma remains highly lethal. How modern chemotherapy reshapes the full mortality profile, including competing non\u2011cancer deaths, is incompletely defined. Using Surveillance, Epidemiology, and End Results (2010\u20132021), we identified 9624 adults (20\u201389 years) with primary pancreatic adenocarcinoma who received systemic chemotherapy. Cause of death (International Classification of Diseases, Tenth Revision) was classified as pancreatic cancer, other cancers, or non\u2011cancer causes. Stage-stratified analyses characterized mortality heterogeneity. Standardized mortality ratios (SMRs) versus the general US population were calculated in SEER*Stat; multivariable Poisson regression assessed risk factors. Temporal patterns were examined across \u22641 year, 1 to 5 years, and &gt;5 years from diagnosis. Over a median follow-up of 14.2 months, 8218 deaths occurred. Pancreatic cancer accounted for 90.6% (n\u2005=\u20057448); non\u2011cancer causes accounted for 6.1% (n\u2005=\u2005498), and other cancers accounted for 3.3% (n\u2005=\u2005272). Non-cancer mortality comprised 7.8% of stage I\/II deaths versus 5.1% in stage III\/IV, reflecting longer survival enabling competing risks. Overall, non\u2011cancer mortality was markedly elevated (SMR 15.38, 95% confidence interval: 14.06\u201316.79), peaking in year 1 (SMR 96.10) and declining thereafter (1\u20135 years, SMR 13.63; &gt;5 years, SMR 3.19). Cardiovascular deaths carried the greatest non\u2011cancer burden (heart disease SMR 9.96; cerebrovascular disease SMR 12.7). Infectious causes showed the highest relative risks (septicemia SMR 20.3; pneumonia\/influenza SMR 88.69), concentrated in the first year. Chronic obstructive pulmonary disease (SMR 17.57) and diabetes (SMR 19.3) were additional contributors. Older patients (70\u201389 years) experienced the steepest early mortality. Suicide risk was strikingly increased (SMR 113.68), underscoring substantial psychological distress. In chemotherapy\u2011treated pancreatic cancer, non\u2011cancer mortality is substantial, time\u2011dependent, and dominated by cardiovascular and infectious causes in the first year after diagnosis. These data support integrated cardio\u2011oncology pathways, aggressive infection prevention, metabolic and pulmonary co\u2011management, and early psychosocial interventions to reduce preventable deaths and improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047381","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:01:53Z","timestamp":1779469313000},"page":"e47381","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Cause-specific mortality in a population-level cohort of pancreatic cancer patients following chemotherapy: A SEER-based study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5644-905X","authenticated-orcid":false,"given":"Zhirong","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, First People\u2019s Hospital of Linping District, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liye","family":"Bei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhejiang Provincial Hospital of TCM, Hangzhou, Zhejiang, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First People\u2019s Hospital of Linping District, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260707","first-page":"233","article-title":"Colorectal cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer.","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial.","volume":"31","author":"Gourgou-Bourgade","year":"2013","journal-title":"J Clin Oncol"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC).","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer.","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/ijc.28990","article-title":"Cancer incidence, survival and mortality: explaining the concepts.","volume":"135","author":"Ellis","year":"2014","journal-title":"Int J Cancer"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/jnci\/djn384","article-title":"Productivity costs of cancer mortality in the United States: 2000\u20132020.","volume":"100","author":"Bradley","year":"2008","journal-title":"JNCI"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer.","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes.","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R19-20260707","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/PAS.0000000000000749","article-title":"The Surveillance, Epidemiology, and End Results (SEER) program and pathology: toward strengthening the critical relationship.","volume":"40","author":"Duggan","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R20-20260707","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jncimonographs\/lgae033","article-title":"History of the Surveillance, Epidemiology, and End Results (SEER) program.","volume":"2024","author":"Friedman","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"R21-20260707","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/MLR.0000000000000073","article-title":"Comparison of SEER treatment data with Medicare claims.","volume":"54","author":"Noone","year":"2016","journal-title":"Med Care"},{"key":"R22-20260707","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/1055-9965.EPI-24-0833","article-title":"Assessing 1-year comorbidity prevalence and its survival implications in Medicare beneficiaries diagnosed with cancer: insights from a new SEER-Medicare resource.","volume":"34","author":"Noone","year":"2025","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies.","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"R24-20260707","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"R25-20260707","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors.","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"R26-20260707","first-page":"6243","article-title":"Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy.","volume":"29","author":"Curra","year":"2021","journal-title":"Support Care Cancer"},{"key":"R27-20260707","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/eurheartj\/ehac666","article-title":"The \u2018Ten Commandments\u2019 for the 2022 European Society of Cardiology Guidelines on cardio-oncology.","volume":"44","author":"Couch","year":"2022","journal-title":"Eur Heart J"},{"key":"R28-20260707","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ehjcvp\/pvac051","article-title":"2022 ESC Guidelines on cardio-oncology: how can we improve the cardiovascular health of patients with cancer and cancer survivors?","volume":"9","author":"L\u00f3pez-Fern\u00e1ndez","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R29-20260707","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R30-20260707","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: associations and relations.","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R31-20260707","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1161\/01.RES.0000146672.10582.17","article-title":"Chemokines in the pathogenesis of vascular disease.","volume":"95","author":"Charo","year":"2004","journal-title":"Circ Res"},{"key":"R32-20260707","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"key":"R33-20260707","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus.","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R34-20260707","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1200\/JCO.2008.20.2267","article-title":"Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer.","volume":"28","author":"Tukenova","year":"2010","journal-title":"J Clin Oncol"},{"key":"R36-20260707","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"R37-20260707","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1634\/theoncologist.8-6-541","article-title":"Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program.","volume":"8","author":"Gloeckler Ries","year":"2003","journal-title":"Oncologist"},{"key":"R38-20260707","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery.","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:01:22Z","timestamp":1783414882000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":37,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047381","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-09-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}